Physician profile
Thomas M Nylk
NPI 1700869708
$4,601.07
in general payments reported to CMS, 2019-2025
27 companies · $2,204 in 2025
The $2,204 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $166 · 2021: $302 · 2022: $277 · 2023: $304 · 2024: $804 · 2025: $2,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,902 · Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,902.22 |
| Food and Beverage | $1,410.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $1,902.22 | 2024-2025 | Venacure 1470 Pro |
| Edwards Lifesciences Corporation | $570.86 | 2020-2025 | Sapien 3 Ultra Resilia, Pascal |
| Novartis Pharmaceuticals Corporation | $538.47 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $328.02 | 2019-2024 | Xarelto |
| Pfizer INC. | $183.51 | 2019-2025 | |
| Boston Scientific Corporation | $129.91 | 2020-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.79 | 2022-2023 | Lifevest |
| Esperion Therapeutics, INC. | $107.22 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $84.48 | 2020-2023 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $79.94 | 2023-2024 | Inpefa |
| Medtronic, INC. | $78.22 | 2021-2024 | Linq II, Mycarelink |
| Biotronik INC. | $60.38 | 2019-2024 | Biomonitor |
| United Therapeutics Corporation | $59.23 | 2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.40 | 2019-2022 | |
| Glaxosmithkline, LLC. | $46.87 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $38.59 | 2019-2025 | Uptravi, Opsynvi |
| Amgen INC. | $32.26 | 2019 | |
| Ge Healthcare | $29.33 | 2021 | |
| Novo Nordisk INC | $28.07 | 2025 | Wegovy |
| Abiomed | $21.32 | 2023 | Impella |
| Abbott Laboratories | $20.73 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $20.08 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.86 | 2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $15.40 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.66 | 2023 | Farxiga |
| Alnylam Pharmaceuticals INC. | $14.20 | 2023 | Onpattro |
| Resmed Corp | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Nylk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.